Straits Times Index
3,347.23 +10.64 (+0.32%) Nikkei
38,923.03 +435.13 (+1.13%) Hang Seng
18,407.08 +327.47 (+1.81%) FTSE 100
8,299.69 +24.31 (+0.29%) Bitcoin USD
68,856.43 +1,164.89 (+1.72%) CMC Crypto 200
1,485.64 +17.70 (+1.21%)
Cybin Inc. (CYBN)
After hours:
| Previous close | 0.3496 |
| Open | 0.3500 |
| Bid | 0.0000 x 1000 |
| Ask | 0.0000 x 1800 |
| Day's range | 0.3420 - 0.3515 |
| 52-week range | 0.2100 - 0.7380 |
| Volume | |
| Avg. volume | 5,074,519 |
| Market cap | 265.892M |
| Beta (5Y monthly) | 1.04 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2200 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.00 |
Business WireCybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024
TORONTO, May 29, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that Amir Inamdar, MBBS, DNB (Psych), MFPM, Cybin’s Chief Medical Officer, and Ellen James, Ph.D., Cybin’s Director, Clinical Development, will participate at the Interdisciplinary Conference on Psychedelic Res
Business WireCybin to Participate in the Alliance Global Partners Healthcare Company Showcase
TORONTO, May 14, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the virtual Alliance Global Partners Healthcare Company Showcase, taking place May 21, 2024.
Business WireCybin Provides Corporate Update and Highlights Upcoming Clinical Milestones
TORONTO, May 06, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, provides a corporate update highlighting recent clinical accomplishments and key upcoming catalysts across its development pipeline.
